A clinical trial reported by Feng et al. used a CAR against EGFR with an appropriate affinity to treat 11 advanced relapsed/refractory non-small cell lung cancer patients with a median dose of 0.97 × 107 cells·kg−1 CAR+ T cells, with two partial response and 5 stable disease outcomes. Here, EGFR is linked to non-small cell lung carcinoma.